GSK's malaria vaccine gradually loses efficacy, small study shows

03/20/2013 | Reuters

The protection rate of GlaxoSmithKline's RTS,S, an experimental malaria vaccine for children, reaches as high as 53% initially, but decreases after eight months, protecting 16.8% of children over a four-year period, according to a study in the New England Journal of Medicine. Since the findings were based on a small, midstage trial, they failed to "provide definitive answers about the duration of protection or how the vaccine candidate works in different malaria transmission settings," a GSK spokeswoman said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC